EXPOSING ANTI-VAPING TACTICS
- Thread starter fbb1964
- Start date
-
- Tags
- anti-vaping
From that article:
"For example, in homes of e-cigarette users, the concentration of indoor airborne nicotine was more than six times higher than in non-users’ homes."
If you follow the link (in that sentence) you get to this:
https://www.sciencedirect.com/science/article/abs/pii/S0013935114003089
And if you are curious abot "cotinine" you'll find this:
"Abstract
A greater incidence of tobacco consumption occurs among individuals with psychiatric conditions including post-traumatic stress disorder (PTSD), bipolar disorder, major depression, and schizophrenia, compared with the general population. Even when still controversial, it has been postulated that smoking is a form of self-medication that reduces psychiatric symptoms among individuals with these disorders. To better understand the component(s) of tobacco-inducing smoking behavior, greater attention has been directed toward nicotine. However, in recent years, new evidence has shown that cotinine, the main metabolite of nicotine, exhibits beneficial effects over psychiatric symptoms and may therefore promote smoking within this population. Some of the behavioral effects of cotinine compared to nicotine are discussed here. Cotinine, which accumulates in the body as a result of tobacco exposure, crosses the blood-brain barrier and has different pharmacological properties compared with nicotine. Cotinine has a longer plasma half-life than nicotine and showed no addictive or cardiovascular effects in humans. In addition, at the preclinical level, cotinine facilitated the extinction of fear memory and anxiety after fear conditioning, improved working memory in a mouse model of Alzheimer’s disease (AD) and in a monkey model of schizophrenia. Altogether, the new evidence suggests that the pharmacological and behavioral effects of cotinine may play a key role in promoting tobacco smoking in individuals that suffer from psychiatric conditions and represents a new potential therapeutic agent against psychiatric conditions such as AD and PTSD."
More at:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3467453/
"For example, in homes of e-cigarette users, the concentration of indoor airborne nicotine was more than six times higher than in non-users’ homes."
If you follow the link (in that sentence) you get to this:
https://www.sciencedirect.com/science/article/abs/pii/S0013935114003089
And if you are curious abot "cotinine" you'll find this:
"Abstract
A greater incidence of tobacco consumption occurs among individuals with psychiatric conditions including post-traumatic stress disorder (PTSD), bipolar disorder, major depression, and schizophrenia, compared with the general population. Even when still controversial, it has been postulated that smoking is a form of self-medication that reduces psychiatric symptoms among individuals with these disorders. To better understand the component(s) of tobacco-inducing smoking behavior, greater attention has been directed toward nicotine. However, in recent years, new evidence has shown that cotinine, the main metabolite of nicotine, exhibits beneficial effects over psychiatric symptoms and may therefore promote smoking within this population. Some of the behavioral effects of cotinine compared to nicotine are discussed here. Cotinine, which accumulates in the body as a result of tobacco exposure, crosses the blood-brain barrier and has different pharmacological properties compared with nicotine. Cotinine has a longer plasma half-life than nicotine and showed no addictive or cardiovascular effects in humans. In addition, at the preclinical level, cotinine facilitated the extinction of fear memory and anxiety after fear conditioning, improved working memory in a mouse model of Alzheimer’s disease (AD) and in a monkey model of schizophrenia. Altogether, the new evidence suggests that the pharmacological and behavioral effects of cotinine may play a key role in promoting tobacco smoking in individuals that suffer from psychiatric conditions and represents a new potential therapeutic agent against psychiatric conditions such as AD and PTSD."
More at:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3467453/
THUS : We are all mad ?
THUS : We are all mad ?
That's the unquestionable fact.
On the other hand, try to calculate how much would they gain by banning vaping (and/or nicotine) and than selling you the same thing (under the different names) for full variety of dissorders on prescription. I think (don't quote me on this) that Alzheimer's alone is about trillion US $ industry.
Similar threads
